Home > Result Summaries: Compounds > GSK2485852 Result Summaries: GSK2485852 GSKStudy ID Phase Title Summary (Download) 115040 phase 1 A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects (0 citation(s)) 116145 n\a Genotypic analysis of baseline and nadir HCV samples from subjects enrolled in the HBI115040 Phase I clinical trial (0 citation(s)) 116146 n\a A retrospective analysis of the IL28 polymorphism of HCV-infected subjects enrolled in the HBI115040 Phase 1 clinical trial (0 citation(s))
